A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non infectious Uveitis
To evaluate the safety and efficacy of filgotinib vs. placebo for the treatment of the signs and symptoms of non-infectious uveitis.
Adult subjects 18 years or older with active, non-infectious
intermediate-, posterior-, or pan-uveitis
18 - 100
Healthy Volunteers Needed
Duration of Participation
Subjects will receive a maximum of 52 weeks of study drug in the
randomized, double-masked trial
Gilead Sciences, Inc.
$50 per visit